Please login to the form below

Not currently logged in
Email:
Password:

chorea

This page shows the latest chorea news and features for those working in and with pharma, biotech and healthcare.

FDA clears Teva's tardive dyskinesia drug Austedo

FDA clears Teva's tardive dyskinesia drug Austedo

The approval is the second for Austedo (deutetrabenazine) after being cleared by the US regulator for chorea - another movement disorder - in patients with Huntington's disease earlier this year.

Latest news

  • FDA approves Teva's Huntington's disease drug at second attempt FDA approves Teva's Huntington's disease drug at second attempt

    FDA approves Teva's Huntington's disease drug at second attempt. Austedo will treat fatal degenerative disorder chorea. ... Results from that trial are due later this year. "Chorea is a major symptom for many living with Huntington disease," said Teva's

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Teva suffered a knockback from the FDA last May for SD-809 when the agency rejected a marketing application for the drug as a treatment for involuntary writhing movements (chorea) associated

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    FDA turns down Teva's Huntington's disease drug. Has requested further analysis on certain metabolites of the chorea candidate. ... Teva has been knocked back by an FDA decision not to approve deutetrabenazine, its candidate drug for chorea associated

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    Teva is also testing deutetrabenazine in Huntington's chorea, and has completed a phase III study with a marketing application pending. ... It also has late-stage trials ongoing in chorea associated with Tourette's syndrome.

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    The takeover of Auspex will give the Israeli firm a product candidate called SD-809 (deutetrabenazine) that has already cleared phase III trials treatment of chorea (involuntary movements) associated with ... SD-809 is also in phase III testing for

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics